Catalyst Event
Innovent Biologics Inc (1801) · Other
From Akros SCHK HK-US Biotech Index (ASHUBIO)
3/23/2026, 12:00:00 AM
Announced that the first participant has been dosed in a Phase 3 clinical study of IBI128 (Tigulixostat), a treatment for gout, in China. [Estimate: Low importance as initial dosing in a Phase 3 trial is a routine update].
Korean Translation
중국에서 통풍 치료제 IBI128(티굴릭소스타트)의 3상 임상 연구 첫 환자 투여를 개시했다고 발표함. [예상: 3상 임상의 첫 환자 투여는 통상적인 진행 과정으로 시장 영향이 제한적이므로 'Low'로 분류함].
Related Recent Events
CSPC Pharmaceutical Group Ltd (1093) · Other
Final dividend of HKD 0.15 per share for FY2025 (total HKD 0.29, +11.5% YoY) with ex-dividend date June 24, 2026; low importance as dividend increases typically result in minor positive price adjustments scheduled.
6/24/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
High importance is estimated due to the potential for significant price volatility for Pfizer's Q1 2026 earnings release and conference call, scheduled.
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release and conference call scheduled; typically results in moderate price movement.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release and conference call scheduled.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Q1 2026 earnings release and conference call for 2026-04-30, estimated to have a low impact of ~1-2% based on historical trends, scheduled.
4/30/2026, 12:00:00 AM
Regeneron Pharmaceuticals Inc (REGN) · Earnings Release
Regeneron is scheduled to report its first quarter 2026 financial and operating results on 2026-04-29. Importance is Medium as earnings typically drive significant price movement, scheduled.
4/29/2026, 12:00:00 AM